GDC-0980 once weekly in patients with Refractory Solid Tumor or NHL

• Research type

  Research Study

• Full title

  AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0980 ADMINISTERED ONCE WEEKLY IN PATIENTS WITH REFRACTORY SOLID TUMORS OR NON-HODGKIN’S LYMPHOMA

• IRAS ID

  11080

• Contact name

  Gordon Jayson

• Contact email

  Gordon.Jayson@christie.nhs.uk or GordonJayson@aol.com

• Sponsor organisation

  Genentech, Inc.

• Eudract number

  2008-006375-79

• ISRCTN Number

  n/a

• Research summary

  Research Summary not published at request of researcher

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  09/H1306/40

• Date of REC Opinion

  13 May 2009

• REC opinion

  Further Information Favourable Opinion